Gritstone bio rises on clinical trial agreement with National Cancer Institute

Gritstone bio

14/02/2023 13:50

** Shares of vaccine maker Gritstone bio Inc  GRTS.O  rise
~3% to $2.78 premarket
    ** Co says it has entered into a clinical trial agreement
with the National Cancer Institute (NCI), an institute of the
U.S. National Institutes of Health 
    ** Co said the trial will evaluate its cancer vaccine
candidate, SLATE-KRAS, in combination with a T-cell therapy
targeting cancers expressing a mutation called Kirsten rat
sarcoma viral oncogene homologue (KRAS) 
    ** The KRAS gene belongs to a class of genes known as
oncogenes which when mutated, have the potential to cause normal
cells to become cancerous
    ** Under the deal, the NCI will identify patients with
advanced cancer expressing KRAS mutation that are eligible and
GRTS will provide the SLATE-KRAS vaccine as requested by NCI for
the trial for the study - GRTS 
    ** Co plans to conduct a mid-stage study separately
evaluating SLATE-KRAS in H2 this year 
    ** Up to last close, stock fell ~52.3% in the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))